vs
SHOE CARNIVAL INC（SCVL）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是SHOE CARNIVAL INC的1.0倍（$311.4M vs $297.2M），Bio-Techne净利率更高（16.4% vs 4.9%，领先11.5%），Bio-Techne同比增速更快（-1.5% vs -3.2%），过去两年SHOE CARNIVAL INC的营收复合增速更高（3.0% vs 1.3%）
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
SCVL vs TECH — 直观对比
营收规模更大
TECH
是对方的1.0倍
$297.2M
营收增速更快
TECH
高出1.7%
-3.2%
净利率更高
TECH
高出11.5%
4.9%
两年增速更快
SCVL
近两年复合增速
1.3%
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $297.2M | $311.4M |
| 净利润 | $14.6M | $51.0M |
| 毛利率 | 37.6% | 66.9% |
| 营业利润率 | 6.3% | 24.2% |
| 净利率 | 4.9% | 16.4% |
| 营收同比 | -3.2% | -1.5% |
| 净利润同比 | -23.9% | 126.0% |
| 每股收益（稀释后） | $0.53 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SCVLTECH
| Q1 26 | — | $311.4M | ||
| Q4 25 | $297.2M | $295.9M | ||
| Q3 25 | $306.4M | — | ||
| Q2 25 | $277.7M | $317.0M | ||
| Q1 25 | $262.9M | $316.2M | ||
| Q4 24 | $306.9M | $297.0M | ||
| Q3 24 | $332.7M | $289.5M | ||
| Q2 24 | $300.4M | $306.1M |
净利润SCVLTECH
| Q1 26 | — | $51.0M | ||
| Q4 25 | $14.6M | $38.0M | ||
| Q3 25 | $19.2M | — | ||
| Q2 25 | $9.3M | $-17.7M | ||
| Q1 25 | $14.7M | $22.6M | ||
| Q4 24 | $19.2M | $34.9M | ||
| Q3 24 | $22.6M | $33.6M | ||
| Q2 24 | $17.3M | $40.6M |
毛利率SCVLTECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | 37.6% | 64.6% | ||
| Q3 25 | 38.8% | — | ||
| Q2 25 | 34.5% | 62.7% | ||
| Q1 25 | 34.9% | 67.9% | ||
| Q4 24 | 36.0% | 65.3% | ||
| Q3 24 | 36.1% | 63.2% | ||
| Q2 24 | 35.6% | 66.4% |
营业利润率SCVLTECH
| Q1 26 | — | 24.2% | ||
| Q4 25 | 6.3% | 18.4% | ||
| Q3 25 | 8.2% | — | ||
| Q2 25 | 4.3% | -7.5% | ||
| Q1 25 | 5.3% | 12.2% | ||
| Q4 24 | 8.0% | 16.0% | ||
| Q3 24 | 9.0% | 13.8% | ||
| Q2 24 | 7.5% | 15.0% |
净利率SCVLTECH
| Q1 26 | — | 16.4% | ||
| Q4 25 | 4.9% | 12.8% | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 3.4% | -5.6% | ||
| Q1 25 | 5.6% | 7.1% | ||
| Q4 24 | 6.3% | 11.7% | ||
| Q3 24 | 6.8% | 11.6% | ||
| Q2 24 | 5.8% | 13.3% |
每股收益（稀释后）SCVLTECH
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.53 | $0.24 | ||
| Q3 25 | $0.70 | — | ||
| Q2 25 | $0.34 | $-0.11 | ||
| Q1 25 | $0.53 | $0.14 | ||
| Q4 24 | $0.70 | $0.22 | ||
| Q3 24 | $0.82 | $0.21 | ||
| Q2 24 | $0.63 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $107.7M | $209.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $683.2M | $2.1B |
| 总资产 | $1.2B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SCVLTECH
| Q1 26 | — | $209.8M | ||
| Q4 25 | $107.7M | $172.9M | ||
| Q3 25 | $91.9M | — | ||
| Q2 25 | $93.0M | $162.2M | ||
| Q1 25 | $123.1M | $140.7M | ||
| Q4 24 | $91.1M | $177.5M | ||
| Q3 24 | $84.5M | $187.5M | ||
| Q2 24 | $69.5M | $152.9M |
总债务SCVLTECH
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
股东权益SCVLTECH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $683.2M | $2.0B | ||
| Q3 25 | $670.7M | — | ||
| Q2 25 | $653.6M | $1.9B | ||
| Q1 25 | $649.0M | $2.0B | ||
| Q4 24 | $635.7M | $2.1B | ||
| Q3 24 | $618.5M | $2.1B | ||
| Q2 24 | $597.8M | $2.1B |
总资产SCVLTECH
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.2B | $2.5B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | $2.6B | ||
| Q1 25 | $1.1B | $2.6B | ||
| Q4 24 | $1.1B | $2.7B | ||
| Q3 24 | $1.1B | $2.7B | ||
| Q2 24 | $1.1B | $2.7B |
负债/权益比SCVLTECH
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.6M | — |
| 自由现金流经营现金流 - 资本支出 | $19.7M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.7% | — |
| 现金转化率经营现金流/净利润 | 2.30× | — |
| 过去12个月自由现金流最近4个季度 | $35.1M | — |
8季度趋势，按日历期对齐
经营现金流SCVLTECH
| Q1 26 | — | — | ||
| Q4 25 | $33.6M | — | ||
| Q3 25 | $13.3M | — | ||
| Q2 25 | $-9.6M | $98.2M | ||
| Q1 25 | $44.5M | $41.1M | ||
| Q4 24 | $17.3M | $84.3M | ||
| Q3 24 | $23.7M | $63.9M | ||
| Q2 24 | $17.1M | $75.5M |
自由现金流SCVLTECH
| Q1 26 | — | — | ||
| Q4 25 | $19.7M | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $-23.0M | $93.3M | ||
| Q1 25 | $36.2M | $31.0M | ||
| Q4 24 | $8.3M | $77.5M | ||
| Q3 24 | $18.2M | $54.7M | ||
| Q2 24 | $6.9M | $57.5M |
自由现金流率SCVLTECH
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | -8.3% | 29.4% | ||
| Q1 25 | 13.8% | 9.8% | ||
| Q4 24 | 2.7% | 26.1% | ||
| Q3 24 | 5.5% | 18.9% | ||
| Q2 24 | 2.3% | 18.8% |
资本支出强度SCVLTECH
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 4.8% | 1.5% | ||
| Q1 25 | 3.2% | 3.2% | ||
| Q4 24 | 3.0% | 2.3% | ||
| Q3 24 | 1.7% | 3.2% | ||
| Q2 24 | 3.4% | 5.9% |
现金转化率SCVLTECH
| Q1 26 | — | — | ||
| Q4 25 | 2.30× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | -1.03× | — | ||
| Q1 25 | 3.04× | 1.82× | ||
| Q4 24 | 0.90× | 2.42× | ||
| Q3 24 | 1.05× | 1.90× | ||
| Q2 24 | 0.99× | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SCVL
暂无分部数据
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
